Environmental
Social
Governance
ESG
Social Responsibility Management
Letter to Stakeholders
Dear Valued stakeholders,
Guided by our unwavering conviction as “the innovative company saving lives,” ST Pharm continues its bold journey toward a sustainable tomorrow. The year 2025 was a meaningful one in which the technological capabilities we have built translated into financial performance, while we embedded social responsibility as a core part of our management.
Swift Response to a Changing Global Environment
The global pharmaceutical and biotechnology industry is undergoing complex changes, including supply chain restructuring, the expansion of ESG regulations, growing demands for climate change response, and the acceleration of digital technologies.
In addition, population aging is driving demand for chronic disease therapeutics, while advances in next-generation treatment technologies are reshaping the industry landscape. These wide-ranging environmental changes are setting new standards for how companies manage their businesses and fulfill their responsibilities. In the CDMO industry in particular, technological innovation, quality competitiveness, environmental responsibility, and supply chain management capabilities—beyond production capacity alone—are emerging as critical competitive factors. Responding to these changes, ST Pharm is strengthening its technology-based competitiveness and expanding its presence in the global CDMO market through responsible management.
In addition, population aging is driving demand for chronic disease therapeutics, while advances in next-generation treatment technologies are reshaping the industry landscape. These wide-ranging environmental changes are setting new standards for how companies manage their businesses and fulfill their responsibilities. In the CDMO industry in particular, technological innovation, quality competitiveness, environmental responsibility, and supply chain management capabilities—beyond production capacity alone—are emerging as critical competitive factors. Responding to these changes, ST Pharm is strengthening its technology-based competitiveness and expanding its presence in the global CDMO market through responsible management.
Delivering Economic Value Through Performance
In 2025, ST Pharm achieved annual revenue of KRW 331.7 billion, representing a 21.2% year-on-year increase, driven by enhanced operational efficiency and expanded orders. Operating profit nearly doubled year-on-year to KRW 54.9 billion. Furthermore, commercial-stage projects accounted for 73% of total oligonucleotide sales, significantly improving the quality of our revenue mix. This demonstrates the trust placed in our technological capabilities by the global market, and this financial growth will serve as a powerful driver for creating even greater social value in the future.
Responsible Management for the Environment and Society
Under the principle that a company’s growth process must also be conducted responsibly, ST Pharm continues systematic management and improvement efforts across all areas of environment, society, and governance. First, we have designated climate change as one of our core material issues and manage it systematically, and we have established a 2050 carbon neutrality roadmap based on our GHG reduction targets. We have also declared our support for the Science Based Targets initiative (SBTi), built a GHG management system, and are expanding the scope of our Scope 3 emissions calculation. In addition, we have established a Product Carbon Footprint (PCF) calculation system to strengthen our data-driven climate response capabilities, and to minimize the negative environmental impacts arising from our business operations, we continuously advance our resource circulation system—including achieving a waste resource circulation rate of 63%.
In terms of social responsibility, we place the safety and health of our employees as our top priority and are strengthening our safety management system, while pursuing ISO 45001 Occupational Health and Safety Management System certification to create a safer working environment. We also contribute to creating inclusive social value by expanding the employment of people with disabilities and strengthening support programs for vulnerable groups, and we actively support our employees’ growth and competency development based on an organizational culture that respects human rights and diversity.
Finally, we are strengthening ESG management for our partners to enhance sustainability across the supply chain and promote responsible supply chain practices.
In terms of social responsibility, we place the safety and health of our employees as our top priority and are strengthening our safety management system, while pursuing ISO 45001 Occupational Health and Safety Management System certification to create a safer working environment. We also contribute to creating inclusive social value by expanding the employment of people with disabilities and strengthening support programs for vulnerable groups, and we actively support our employees’ growth and competency development based on an organizational culture that respects human rights and diversity.
Finally, we are strengthening ESG management for our partners to enhance sustainability across the supply chain and promote responsible supply chain practices.
A Roadmap for Sustainable Future Growth through Business Diversification and Transformation
Under the mission of being “the innovative company saving lives,” ST Pharm is executing a mid- to long-term vision to become a global top-tier CDMO. In the short term, we will solidify our market leadership and accelerate sales growth through the successful operation of the 2nd Oligo Plant and the establishment of a “client-centric mindset.” In the mid term, we will strengthen our manufacturing competitiveness in line with global standards by introducing automation and an Occupational Exposure Limit (OEL) system at the Sihwa and Banwol Campuses, and we will complete a fundamental transformation of the organization through the advancement of our IT systems and talent development. In the long term, we will diversify our business portfolio beyond the existing oligonucleotide field into xRNA and cell and gene therapies, securing future growth drivers that will shape the next-generation therapeutics market. Through this phased strategy, we will create both economic value and sustainable value while earning the continued trust of our stakeholders.
A Future Together with Our Stakeholders
ST Pharm’s growth has been made possible by the trust and cooperation of all our stakeholders, including our employees, clients, partners, local communities, and investors. Going forward, we aim to be a company that achieves both financial performance and ESG value, contributing to human health and well-being and fulfilling our social responsibility through innovative pharmaceutical manufacturing.
We appreciate your continued interest and support.
Thank you.
President and CEO of ST Pharm
Mooje Sung
ST Pharm enacts 『The Code of Corporate Ethics』 to fulfill Dong-A Socio Group's mission of 'Company grows together with society', which means Jeong-Do (Right Path) management, that is, social responsibility.
This code succeeds Dong-A Socio Group's Jeong-Do Management philosophy.
n order to fulfill our responsibilities as a global company with the vision of ‘The innovative company saving lives’, we will strive for responsible management activities by announcing the principles of business and the practice methods of all employees.
The Code of Corporate Ethics PDF
Business Principles
ST Pharm is making great efforts to achieve the goal of being ‘The innovative company saving lives’. In a complex and uncertain world that is constantly changing, achieving the goals will require a different approach than other companies take.
We accept the state-of-the art science and technology, produce new products, and intend to ‘contribute to improving human health and welfare by fulfilling corporate social responsibilities in accordance with social justice and manufacturing excellent pharmaceutical products’ based on the belief that strengthening trust with the world comes first rather than pursuing economic efficiency.
Accordingly, we define ST Pharm members, ST Pharm partners, ST Pharm local communities, ST Pharm consumers, and ST Pharm investors as the targets of social responsibility, and establish five business principles to create a virtuous cycle of social responsibility.
We accept the state-of-the art science and technology, produce new products, and intend to ‘contribute to improving human health and welfare by fulfilling corporate social responsibilities in accordance with social justice and manufacturing excellent pharmaceutical products’ based on the belief that strengthening trust with the world comes first rather than pursuing economic efficiency.
Accordingly, we define ST Pharm members, ST Pharm partners, ST Pharm local communities, ST Pharm consumers, and ST Pharm investors as the targets of social responsibility, and establish five business principles to create a virtuous cycle of social responsibility.
Principle 1. Human Right Management
ST Pharm considers the health and happiness of the employees the most important in order to create a company where employees are happy. The company's development begins with the happiness of its employees, and happy employees gather to make the company healthy.
Principle 2. Environment Management
ST Pharm makes efforts to protect the environment in which the present and future generations will live, and to contribute to climate change mitigation and reducing emission of greenhouse gases. We will meet the expectations of stakeholders through environmental management that protects the local and global environment.
Principle 3. Compliance Management
ST Pharm acts honestly to build partnerships and mutual trust among stakeholders with the goal of realizing social justice. We are increasing work efficiency by establishing fair standards internally and pursuing sustainable development through cooperation and responsible management among group companies.
Principle 4. Consumer-oriented Management
ST Pharm takes the lead in developing products from the consumer's point of view and protecting consumer rights and interests in order to provide excellent products and services to consumers. ST Pharm will do its best to reasonably, promptly and accurately take account of customer opinions, respond to complaints and prevent them in advance in order to understand each other, trust and become one with consumers.
Principle 5. Social Contribution Management
The development of new drugs in ST Pharm is an activity to contribute to society. It is ST Pharm's mission and social responsibility to develop good medicine, heal sick people, and help everyone live a healthy and prosperous life.
Social Responsibility Management Committee
In response to a management environment in which the importance of non-financial value is increasing, ST Pharm defines sustainability from the perspective of “social responsibility” and has built and operates a governance system to systematically manage the implementation of its social responsibilities.
To this end, we established the “ST Pharm Code of Corporate Ethics” and set up the Social Responsibility Management Committee, which oversees sustainability as a whole.
Social Responsibility Management Governance
Category |
Organization |
Leadership |
Composition |
Roles & Responsibilities |
|
Highest Decision-Making Body
|
Board of Directors
|
Chairman
|
Internal Directors
Outside Directors |
|
|
Company-wide Oversight Committee
|
Social Responsibility Management Committee
|
CEO
|
|
|
|
Subcommittees
|
EHS Management Committee
|
Chief Safety Officer
|
EHS-related C-Level
|
|
|
Human Rights Committee
|
Head of Business Administration Division
|
HR & General Affairs Team
|
|
|
|
Anti-Bribery Audit Committee
|
Director of
Anti-Bribery Compliance Function |
Corporate Audit Team, Internal Auditors
|
|
|
|
Manufacturing Quality Committee
(GMP Committee) |
Manufacturing Quality Committee Chairperson
(GMP Chairperson) |
Team Leaders of Quality Assurance, Quality Control, Production, Warehouse Operation, Facility Operation & Supporting and EHS
|
|
|
|
Implementing Organization
|
Sustainability Management Team
|
-
|
-
|
|
Supply Chain Management
As global supply chain due diligence regulations (CSDDD) are strengthened and corporate supply chain risks are directly linked to reputation, partner management is emerging as an important factor that determines business stability. Disruptions in raw material supply or environmental and human rights issues at partners can lead to financial losses such as contract termination and to a decline in corporate reputation. Accordingly, ST Pharm has established a Code of Conduct for Business Partners and regularly conducts ESG self-assessments and ESG on-site audits for core partners to encourage partners' voluntary improvement. These systematic supply chain management efforts enhance the stability of raw material supply and serve as a foundation for responding to global pharmaceutical clients' demands for a sustainable supply chain.
Business Partners Policy PDF
Code of Conduct for Business Partners PDF
Supply Chain Management Governance
Category |
Organization |
Leadership |
Composition |
Roles & Responsibilities |
|
Highest Decision-Making Body
|
Board of Directors
|
Chairman
|
Internal Directors,
Outside Directors |
|
|
Company-wide Oversight Committee
|
Social Responsibility Management Committee
|
CEO
|
Management
|
|
|
Implementing Organization
|
Sustainability Management Team
|
-
|
-
|
|
|
Sourcing & Procurement Team
|
-
|
-
|
|
Materiality Assessment Process
ST Pharm conducts a double materiality assessment based on ESRS, GRI Standards, and KSSB Sustainability Disclosure Standards. The double materiality assessment evaluates the financial effects of sustainability issues on corporate value and the impact of corporate management on the environment and society, and we observe the following procedures to systematically conduct this assessment.
Material Issue Impact Assessment Results
Managing Material Issues